FMX MEXICAN ECONOMIC DEVELOPMENT INC

MIXED Impact: 6/10 6-K
Horizon weeks Filed Apr 30, 2026 Processed 1mo ago SEC 0001104659-26-052276
Notable filing: 6-K
Latest settled — T+20d ⚠ clustered
FMX ▲ +2.22% at T+20d
NEUTRAL call ✓ call won +2.22% · α vs SPY -2.75% · entry $118.24 → $120.86
Next anchor: T+60d in 7w
Currently $122.20 · +3.35% from $118.24 entry
Entry anchored
Apr 29, 03:59 PM ET
via Databento tick
T+1d
+1.46%
call +1.46% · α +1.24%
$119.97
settled 6w ago
T+5d
+3.32%
call +3.32% · α +1.60%
$122.17
settled 5w ago
T+20d
+2.22%
call +2.22% · α -2.75%
$120.86
settled 12d ago
T+60d
call — · α —
in 7w

Price Chart

Loading chart...

Executive Summary

FEMSA reported Q1 2026 results with consolidated revenue up 6.1% YoY to Ps. 207,784 million and operating income up 5.5% to Ps. 14,314 million, driven by strong performance at OXXO Mexico (revenue +8.3%, operating income +20.9%) and Americas & Mobility (+12.9% revenue). However, Coca-Cola FEMSA's operating income declined 2.3%, and Health operating income fell 14.2%. Net consolidated income surged 97.3% to Ps. 17,639 million, but excluding a one-time gain from the BradyPLUS/Imperial Dade merger, net income declined 36.4% to Ps. 5,688 million due to higher financing costs and FX losses. The company also announced a non-renewal of a medication dispensing agreement in Colombia and declared ordinary and extraordinary dividends.

Actionable Insight

The core retail business (OXXO Mexico) is performing well with accelerating margins, but Coca-Cola FEMSA's operating income decline and the 36.4% drop in adjusted net income are concerning. The non-renewal of the Colombia medication dispensing agreement adds uncertainty to the Health segment. Monitor the Q2 2026 conference call for guidance on Coca-Cola FEMSA margin recovery and the impact of the Cruz Verde contract termination. The elevated leverage (1.24x ND/EBITDA) from aggressive capital returns warrants watching.

Key Facts

  • FEMSA consolidated revenue grew 6.1% YoY to Ps. 207,784 million in Q1 2026; on a comparable basis, revenue grew 8.5%.
  • Consolidated income from operations increased 5.5% to Ps. 14,314 million; on a comparable basis, operating income grew 12.1%.
  • OXXO Mexico revenue grew 8.3% to Ps. 74,424 million, with operating income up 20.9% to Ps. 5,629 million.
  • Coca-Cola FEMSA revenue grew 1.1% to Ps. 70,925 million, but operating income declined 2.3% to Ps. 9,032 million.
  • Health division revenue grew 0.9% to Ps. 22,175 million, but operating income declined 14.2% to Ps. 657 million.
  • Consolidated net income was Ps. 17,639 million, up 97.3% YoY, but excluding a one-time gain from the BradyPLUS/Imperial Dade merger, net income was Ps. 5,688 million, a decline of 36.4%.
  • Net Debt/EBITDA ex-KOF increased to 1.24x from 0.69x in 1Q25, reflecting cash outflows for dividends (Ps. 47,218 million) and share repurchases (Ps. 16,055 million) over the last twelve months.
  • Cruz Verde Colombia notified EPS Sanitas of its decision not to renew the medication dispensing agreement under the Mandatory Health Plan, set to expire on September 30, 2026.
  • Shareholders approved ordinary dividend of Ps. 4.7520 per BD Unit and extraordinary dividend of Ps. 8.0597 per BD Unit, payable in four installments.

Financial Impact

Consolidated revenue grew 6.1% to Ps. 207,784 million; operating income up 5.5% to Ps. 14,314 million; net income up 97.3% to Ps. 17,639 million (but down 36.4% excluding one-time gain). Coca-Cola FEMSA operating income down 2.3%.

revenueoperating incomenet incomenet debt/EBITDA

Risk Factors

  • Coca-Cola FEMSA operating income declined 2.3% YoY, with Mexico & Central America operating income down 17.4% due to excise tax increases and restructuring costs.
  • Adjusted net income (ex-one-time gain) fell 36.4% due to higher financing costs, FX losses, and absence of discontinued operations income.
  • Net debt/EBITDA ex-KOF rose to 1.24x from 0.69x a year ago, driven by large dividend and buyback payouts.
  • Health division operating income declined 14.2%, and the non-renewal of the Cruz Verde Colombia medication dispensing agreement creates revenue risk for that segment.
  • Europe same-store sales declined 2.7% YoY, indicating soft consumer trends in Germany.

Market Snapshot

Exchange
NYSE
Sector
Bottled & Canned Soft Drinks & Carbonated Waters
Analyst Consensus
85% bullish (20 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001104659-26-052276
Document: tm2613197d1_6k.htm0001104659-26-052276
Document: 0001104659-26-052276-index-headers.html0001104659-26-052276
Document: 0001104659-26-052276-index.html0001104659-26-052276
Document: 0001104659-26-052276.txt0001104659-26-052276
8 reports for FMX
Performance horizon
Filters
Rows
Reports for FMX — sortable, filterable
Type Now
Jun 8, 2026
1d ago
6-K
BULLISH ★ 5/10
$122.79 awaiting T+5awaiting T+5$122.20 (−0.48%)
May 28, 2026
12d ago
6-K
NEUTRAL ★ 2/10
$119.03 $122.88▲ +3.23%▲ +5.76%$122.20 (+2.66%)
Apr 30, 2026
5w ago
Press Release
NEUTRAL ★ 4/10
$118.24 $122.17▲ +3.32%▲ +1.60%$122.20 (+3.35%)
Apr 30, 2026
5w ago
6-K
MIXED ★ 6/10
$118.24 $122.17▲ +3.32%▲ +1.60%$122.20 (+3.35%)
Apr 24, 2026
6w ago
Press Release
NEUTRAL ★ 5/10
$113.04 $118.91▲ +5.19%▲ +4.79%$122.20 (+8.10%)
Apr 24, 2026
6w ago
6-K
NEUTRAL ★ 3/10
$113.04 $118.91▲ +5.19%▲ +4.79%$122.20 (+8.10%)
Apr 24, 2026
6w ago
20-F
MIXED ★ 5/10
$113.04 $118.91▲ +5.19%▲ +4.79%$122.20 (+8.10%)
Mar 23, 2026
11w ago
Press Release
NEUTRAL ★ 5/10
$101.30 $106.43▲ +5.06%▲ +8.63%$122.20 (+20.63%)
Showing 8 of 8

US Market Status

Market Closed — Opens Thu (10h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access